Zeng Y - Search Results

1

The Class I PI3K inhibitor S14161 induces autophagy in malignant blood cells by modulating the Beclin 1/Vps34 complex.

Wang S, Li J, Du Y, Xu Y, Wang Y, Zhang Z, Xu Z, Zeng Y, Mao X, Cao B. Wang S, et al. Among authors: zeng y. J Pharmacol Sci. 2017 Aug;134(4):197-202. doi: 10.1016/j.jphs.2017.07.001. Epub 2017 Jul 19. J Pharmacol Sci. 2017. PMID: 28779993 Free article.

2

Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization.

Han K, Xu X, Chen G, Zeng Y, Zhu J, Du X, Zhang Z, Cao B, Liu Z, Mao X. Han K, et al. Among authors: zeng y. J Hematol Oncol. 2014 Jan 15;7:9. doi: 10.1186/1756-8722-7-9. J Hematol Oncol. 2014. PMID: 24428908 Free PMC article.

3

A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma.

Zhu J, Wang M, Yu Y, Qi H, Han K, Tang J, Zhang Z, Zeng Y, Cao B, Qiao C, Zhang H, Hou T, Mao X. Zhu J, et al. Among authors: zeng y. Oncotarget. 2015 Jan 1;6(1):185-95. doi: 10.18632/oncotarget.2688. Oncotarget. 2015. PMID: 25474140 Free PMC article.

4

SC06, a novel small molecule compound, displays preclinical activity against multiple myeloma by disrupting the mTOR signaling pathway.

Han K, Xu X, Xu Z, Chen G, Zeng Y, Zhang Z, Cao B, Kong Y, Tang X, Mao X. Han K, et al. Among authors: zeng y. Sci Rep. 2015 Sep 2;5:12809. doi: 10.1038/srep12809. Sci Rep. 2015. PMID: 26329846 Free PMC article.

5

Mebendazole elicits potent antimyeloma activity by inhibiting the USP5/c-Maf axis.

Chen XH, Xu YJ, Wang XG, Lin P, Cao BY, Zeng YY, Wang Q, Zhang ZB, Mao XL, Zhang T. Chen XH, et al. Acta Pharmacol Sin. 2019 Dec;40(12):1568-1577. doi: 10.1038/s41401-019-0249-1. Epub 2019 Jun 13. Acta Pharmacol Sin. 2019. PMID: 31197245 Free PMC article.

6

Suppression of the USP10/CCND1 axis induces glioblastoma cell apoptosis.

Sun T, Xu YJ, Jiang SY, Xu Z, Cao BY, Sethi G, Zeng YY, Kong Y, Mao XL. Sun T, et al. Among authors: zeng yy. Acta Pharmacol Sin. 2021 Aug;42(8):1338-1346. doi: 10.1038/s41401-020-00551-x. Epub 2020 Nov 12. Acta Pharmacol Sin. 2021. PMID: 33184448 Free PMC article.

7

TRIM25 activates AKT/mTOR by inhibiting PTEN via K63-linked polyubiquitination in non-small cell lung cancer.

He YM, Zhou XM, Jiang SY, Zhang ZB, Cao BY, Liu JB, Zeng YY, Zhao J, Mao XL. He YM, et al. Acta Pharmacol Sin. 2022 Mar;43(3):681-691. doi: 10.1038/s41401-021-00662-z. Epub 2021 Apr 30. Acta Pharmacol Sin. 2022. PMID: 33931764 Free PMC article.

8

The Ring Finger Protein RNF6 Induces Leukemia Cell Proliferation as a Direct Target of Pre-B-cell Leukemia Homeobox 1.

Xu X, Han K, Tang X, Zeng Y, Lin X, Zhao Y, Zhang Z, Cao B, Wu D, Mao X. Xu X, et al. Among authors: zeng y. J Biol Chem. 2016 Apr 29;291(18):9617-28. doi: 10.1074/jbc.M115.701979. Epub 2016 Mar 12. J Biol Chem. 2016. PMID: 26971355 Free PMC article.

9

An inhibitor of cholesterol absorption displays anti-myeloma activity by targeting the JAK2-STAT3 signaling pathway.

Xu X, Han K, Zhu J, Mao H, Lin X, Zhang Z, Cao B, Zeng Y, Mao X. Xu X, et al. Among authors: zeng y. Oncotarget. 2016 Nov 15;7(46):75539-75550. doi: 10.18632/oncotarget.12265. Oncotarget. 2016. PMID: 27705908 Free PMC article.

10

Ring finger protein 6 promotes breast cancer cell proliferation by stabilizing estrogen receptor alpha.

Zeng Y, Xu X, Wang S, Zhang Z, Liu Y, Han K, Cao B, Mao X. Zeng Y, et al. Oncotarget. 2017 Mar 21;8(12):20103-20112. doi: 10.18632/oncotarget.15384. Oncotarget. 2017. PMID: 28223545 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15,612 results

Search Page

Filters